Background and Objectives: To determine the prevalence of HCV-RNA-positive plasma pools in Belgium, to validate our PCR method and to increase the safety of the released blood products. Materials and Methods: Plasma pools consisting each of about 5,000 donations from Belgian unpaid volunteer blood donors were analysed by PCR for the presence of HCV RNA. Two different extraction methods were compared and validated. Results: Two out of 367 plasma pools were found to be HCV RNA positive and were discarded. For one of these two pools, the look-back procedure identified an anti-HCV-negative contaminated donation. The HCV genotype of both the contaminated pool and the donation was 5a, a genotype rare in Europe. The viral load of the preseroconverted donation was 2.9 × 107 gEq/ml according to the bDNA method. Conclusion: In the case of plasma derivatives, various important steps are already included to increase safety. Nucleic acid testing of manufacturing plasma pools ensures that viral load in the starting material is as low as possible.

1.
Dow BC, Follett EAC, Munro H, Buchanan I, Roy K, McOmish F, Yap PL, Simmonds P: Failure of 2nd- and 3rd-generation HCV ELISA and RIBA to detect HCV polymerase chain reaction-positive donations. Vox Sang 1994;67:236–237.
2.
Bassett SE, Brasky KM, Lanford RE: Analysis of hepatitis C virus inoculated chimpanzees reveals unexpected clinical profiles. J Virol 1998;72:2589–2599.
3.
Vrielink H, van der Poel CL, Reesink HW, Zaaijer HL, Lelie PN: Transmission of hepatitis C virus by anti-HCV-negative blood transfusion. Vox Sang 1995;68:55–56.
4.
Saldanha J, Minor P: Incidence of hepatitis C virus RNA in anti-HCV-negative plasma pools and blood products. Vox Sang 1996;70:232–234.
5.
da Silva Cardoso M, Koerner K, Epple S, Kubanek B: The safety of blood products derived from plasma pools: The positive impact of anti-HCV screening on the quality of such products. Vox Sang 1996;71:184–186.
6.
Eastlund T: Monetary blood donation incentives and the risk of transfusion-transmitted infection. Transfusion 1998;38:874–882.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.